BioCryst Pharmaceuticals Inc.

About BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals, Inc. is a global biotechnology company focused on developing novel therapeutics for rare diseases, particularly hereditary angioedema (HAE). Founded in 1986, with over three decades of experience in drug discovery, development, and commercialization, BioCryst aims to deliver first-in-class or best-in-class oral small-molecule and protein therapeutics. Their mission is to empower patients by listening to their needs, breaking new ground with innovative science, and fostering a transparent, supportive culture.

Products & Services

Rare Disease Pharmaceuticals:Medicines focused on hereditary angioedema (HAE) and other rare diseases, developed using a structure-guided approach combining biology, medicinal chemistry, and advanced technologies to create oral small-molecule and protein therapeutics.

Specialties

Rare Disease Therapeutics Hereditary Angioedema (HAE) Treatments Structure-Guided Drug Design Oral Small-Molecule Therapeutics Protein Therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 450000000 MR: - FA: 450 million FAN: 450000000	D: 2023-04-18 FD: 2023-04-18	1 investors

Debt Latest

2023-04-18

$450.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

W

William Spencer, III

Businessman

C

Charles Bugg, MD

Chairman and Chief Executive Officer

J

John Montgomery, PhD

Medicinal Chemist

Y

Yarlagadda S. Babu

Chief Discovery Officer

J

Jon P. Stonehouse

Chief Executive Officer

B

Bill Sheridan, MD

Chief Medical Officer

View 11 more team members with Pro

Unlock Full Team Directory

Recent News